Amrinone and milrinone are phosphodiesterase inhibitors with positive inotropic effects useful for the treatment of ventricular dysfunction after cardiac surgery. Forty-four patients undergoing elective cardiac surgery at four centers received either amrinone (n = 22) or milrinone (n = 22) in a randomized, blind fashion. Immediately after separation from cardiopulmonary bypass (CPB), two bolus doses of either amrinone 0.75 mg/kg or milrinone 25 pg/kg were administered over 30 s, separated by 5 min. Hemodynamic measurements were recorded before each dose and at the end of the lo-mm study. Both amrinone and milrinone increased the cardiac index (48% vs 52%, P = not significant [NS] for amrinone and milrinone, respectively). There was a small increase in mean arterial pressure (MAP) after amrinone administration (from 68 + 3 to 72 + 3 mm Hg at 10 min, P < 0.05) with no significant change in MAP after milrinone administration. Central venous pressure was significantly higher in the amrinone group at baseline and 5 mm (12 vs 10 mm Hg and 11 vs 10 mm Hg, respectively; P < 0.05). Systemic and pulmonary vascular resistances decreased significantly and to a similar extent after either amrinone or milrinone administration.
Phenylephrine was required in 11 of 22 patients receiving amrinone and in 11 of 22 patients receiving milrinone to maintain arterial blood pressure. The proportion of patients requiring an intravascular volume infusion (15 of 22 vs 17 of 22, P = NS) and the total fluid volume infused were similar (402 + 57 vs 350 t 49 mL, I' = NS for amrinone and milrinone, respectively). Amrinone and milrinone seem to have similar hemodynamic effects after CPB, with the exception of blood pressure, although the need for vasopressor support of blood pressure did not differ. Selection between these two drugs may include nonhemodynamic considerations such as cost. Implications: Amrinone and milrinone are drugs that improve cardiac contraction. Their effects have never been directly compared in patients. We found that amrinone and milrinone produced similar hemodynamic effects in adult patients undergoing cardiac surgery. Choice between the two drugs can be based on nonhemodynamic considerations such as cost. (Anesth Analg 1998; 86:683-90 683 however, the clinical effectiveness of these two drugs has never been compared directly. Given their identical mechanism of action, and based on our clinical experience with the two drugs, we hypothesized that both amrinone and milrinone would produce similar hemodynamic effects. The drugs differ primarily in their pharmacokinetic (6,s) and side effect profilesmilrinone has a lower incidence of associated thrombocytopenia during chronic administration (9). In adult doses, milrinone is also less expensive than amrinone in some settings. Such factors would favor the use of milrinone if its hemodynamic effectiveness were equal to that of amrinone. We directly compared the hemodynamic effects of amrinone and milrinone immediately after separation from CPB in a blind, prospective, randomized, multicenter trial conducted in three teaching centers and one nonteaching site.
Methods
Our study was reviewed and approved by our institutional review boards. All patients gave written, informed consent to participate in the study. Patients undergoing CABG or valvular surgery were asked to participate; 44 patients were entered into the study based on their initial cardiac index (CI) after separation from CPB (Bowman Gray n = 10, Vermont n = 10, High Point y1 = 14, Texas n = 10). A power analysis was performed using pooled variance derived from our previous data using milrinone (6) . In this earlier study, the mean increase in CI 10 min after 50 pg/kg of milrinone was 1.07 L * min? * m-* with a variance of kO.6 L * min-' * m-*. We felt that a difference in drug effect of 1 L/min in cardiac output between amrinone and milrinone would be significant and important. This would translate into a CI of 0.6 L * min-l. m-* based on an average body surface area of 1.7 m2. For a pooled variance of 0.6 L * min-' * m-*, setting (Y = 0.05 and p = 0.20 (80% power), to determine a difference of 0.6 L * mm-' . m-' in drug effect would require 22 patients per group. Patients were excluded if they had experienced a myocardial infarction within the previous 7 days, displayed preoperative ventricular arrhythmias, or required inotropic drugs or intraaortic balloon counterpulsation either preoperatively or intraoperatively before or during separation from CPB. In addition, patients with a CI 2 2.7 L * min-'
. m-* after separation from CPB were excluded.
Patients were sedated with IM morphine (~0.1 mg/kg) and either oral lorazepam (550 pg/kg) or IM scopolamine (56 pg/kg) before their arrival in the surgical suite. IV and radial artery catheters were inserted percutaneously with local anesthesia. A balloon-tipped, thermodilution pulmonary artery catheter was inserted either using local anesthesia with the patient awake, or after induction of general anesthesia, according to the usual practices of participating centers. Patients were anesthetized with IV fentanyl (50-75 pg/kg) or sufentanil (lo-20 pg/kg), and midazolam (0.1-0.3 mg/kg).
Paralysis was maintained with either vecuronium or pancuronium. If potent inhalational anesthetics (enflurane or isoflurane) were used, they were discontinued on rewarming. The CPB circuits were primed with blood-free solutions, and cardioplegia was delivered intermittently at 20-to 30 -min intervals in all patients. The method of delivery of cardioplegia varied among the institutions (see Table 1 ). During rewarming, phenylephrine was infused (lo-100 pg/min) when bypass flow ~2.5 L * min-i * m-* failed to maintain mean arterial pressure (MAP) >60 mm Hg. In those patients requiring phenylephrine during rewarming, the infusion was continued after separation from CPB. Phenylephrine administration was begun during the study interval as needed to maintain a MAP of 65 mm Hg. No additional anesthetics were given between separation from CPB and completion of all study hemodynamic measurements. All patients not in sinus rhythm at a rate faster than 80 bpm were paced at a rate of 90 bpm via epicardial pacemaker leads. On separation from CPB, patients were transfused from the reservoir of the pump oxygenator to establish and maintain the pulmonary artery diastolic pressure above 10 mm Hg. Duplicate baseline measurements of cardiac output were performed within 2 min after separation from CPB; if the first two measurements differed by more than 20%, a third measurement was obtained. All measurements were included in the mean hemodynamic calculations unless there were clear-cut reasons for excluding them (e.g., accidental incomplete cardiac output injection). The following hemodynamic values were also recorded at all measurement times: heart rate, systemic and pulmonary arterial blood pressures, pulmonary artery occlusion pressure, and central venous pressure.
Inotropic drugs were administered in a randomized, blind fashion. Patients were randomly assigned to receive either amrinone or milrinone using a random number table; group assignments were made for all institutions and sealed in numbered envelopes before starting the study. Two doses of amrinone (0.75 mg/kg) or milrinone (25 pg/kg) were diluted to 20 mL with isotonic sodium chloride solution, and the syringe was covered with aluminum foil (to assure blinding because milrinone is clear and amrinone is yellow).
Drug doses were based on those demonstrated to produce maximal increases in CI in cardiac surgical patients (6, 8) . Study drugs were prepared and administered by an investigator not involved in subsequent data collection. After baseline hemodynamic values were recorded, each patient was given the drug bolus over 30 s. A second complete set of hemodynamic data was recorded between 4.5 and 5 min after the first bolus of inotrope. A second, identical bolus of the same inotrope was given lV over 30 s starting 5 min after administration of the first dose. A third and final set of complete hemodynamic data was recorded between 9.5 and 10 min after the first bolus of inotrope was given. Two separate boluses separated by a 5-min interval were given to derive doseresponse information in addition to the overall effect of the loading dose. The amrinone and milrinone used in this study were provided by Sanofi Winthrop Pharmaceuticals (New York, NY). Nonparametric demographic data (gender, phenylephrine use, preoperative New York Heart Association class, preoperative antianginal drugs, type of cardioplegia, and type of surgery) were analyzed using 2 testing. The remainder of the data was analyzed using mixed models repeated-measures analysis of variance. Fisher's pooled least significant difference was used to correct for multiple comparisons. All data are reported as mean ? SEM, and P < 0.05 was considered significant.
Results
Twenty-two patients received amrinone, and 22 patients received milrinone. There were equal numbers of patients in each drug treatment group at each study site. Randomization was done before the study began to assure equal allocation to treatment groups with 10 patients at each study site. High Point enrolled four additional patients using random number allocation. There were no differences among study sites with respect to patient age, weight, height, gender distribution, preoperative ejection fraction, or phenylephrine use during the study interval (Table 1) . Duration of CPB and aortic cross-clamping were significantly shorter at High Point than at the other three centers. The preoperative ejection fraction was not determined at the time of cardiac catheterization in 2 patients in the High Point group-both patients subsequently received amrinone. The type of cardioplegia solution used and the method of delivery varied among institutions (Table 1) .
There were no significant demographic differences between amrinone and milrinone treatment groups ( Table 2) . The majority of patients in both treatment groups underwent CABG surgery alone; a minority underwent concomitant or isolated valve replacements. Of the 44 patients, 5 underwent surgery other than CABG: 2 CABG/MVR (mitral regurgitation), 1 CABG/AVR (aortic stenosis), 2 AVR (aortic stenosis), and 1 atria1 myxoma resection. The type of cardioplegia solution used and the method of delivery were similar in both treatment groups (Table 2) . Treatment groups were also similar with respect to preoperative New York Heart Association classification and antianginal drug use (Table 2) .
Both amrinone and milrinone produced similar increases in CI (amrinone 2.3 ? 0.1 to 3.4 t 0.1 L . miI--l . m-2 at 10 min, milrinone 2.3 ? 0.1 to 3.5 k 0.2 L * mir-r * me2 at 10 min) during the study interval ( Figure 1 ). There was a tendency for the increase in CI to appear earlier (by 5-min after the first dose) in the amrinone than the milrinone treatment group, but this did not reach statistical significance.
Of the 22 patients in each treatment group, 11 (50%) received phenylephrine during the study interval, and this was typically initiated before amrinone/ milrinone administration. There was no change in MAP after milrinone in either the group receiving RATHMELL ET AL.
ANESTH ANALG AMRINONE VS MILRINONE AFTER CARDIAC SURGERY 1998:86:683-90 bNot estimated during cardiac catheterization in two patients in this group. phenylephrine or the group not receiving phenylephrine ( Figure 2 ). By 5 min after amrinone administration, MAP increased significantly in both those patients who required phenylephrine (69 + 4 vs 76 + 2 mm Hg at baseline versus 5 min, P < 0.05) and those who did not require phenylephrine (68 +-5 vs 78 ? 3 mm Hg at baseline versus 5 min, P < 0.05). By 10 min after amrinone administration, the average MAP was no different from baseline values in patients requiring phenylephrine (69 + 4 vs 69 + 2 mm Hg at baseline versus 10 min) but remained significantly increased in the group not requiring phenylephrine (68 + 5 vs 76 5 5 mm Hg at baseline versus 10 min, P < 0.05). There were no significant changes in MAP after the administration of milrinone. Central venous pressure was significantly higher in the amrinone group at baseline and 5 min (12 vs 10 mm Hg and 11 vs 10 mm Hg, respectively). There were no differences between treatment groups or over time in pulmonary artery occlusion pressure, heart rate, or mean pulmonary artery pressure (Table 3) . (PHE) during the study interval to maintain MAP >65 mm Hg versus those not requiring PHE. The first AMR or MIL dose was given immediately after baseline hemodynamic measurements were completed; the second dose was given immediately after the 5-min measurement. *P < 0.05 for MAP 5 and 10 mm after administration versus baseline; tP < 0.05 for MAP after AMR versus MIL administration.
Most patients were paced via epicardial pacemaker electrodes in either atria1 or dual-chamber modes at a rate of 90 bpm (19 of 22 in the amrinone group and 20 of 22 in the milrinone group were paced during at least once during the study interval). In several patients, the pulse generator was turned either on or off during the study interval; thus, the number of patients paced at each time point varied (Figure 3 ). In those patients whose pulse generator was on during hemodynamic measurements, there was no significant change in heart rate during the study interval. ln those patients whose pulse generator was off during hemodynamic measurements, there was a modest increase in heart rate during the study interval, which was not statistically significant (amrinone 90 t 1 bpm at baseline, 99 t 8 bpm at 5 min, and 105 t 11 bpm at 10 min; milrinone 84 t 4 bpm at baseline, 90 t 6 bpm at 5 min, and 99 t 6 bpm at 10 min; P = not significant [NS] for baseline versus 5 and 10 min and amrinone versus milrinone).
A significant decrease was seen in both systemic and pulmonary vascular resistances after amrinone or milrinone administration (Table 3) the study interval (Paced) versus those whose pacemaker was inactive during the study interval.
The first AMR or MIL dose was given immediately after baseline hemodynamic measurements were completed; the second dose was given immediately after the 5 -min measurement.
The number shown in parentheses beside each data point is the number of patients in each group. There were no significant differences in heart rate either within treatment groups (baseline versus 5 and 10 min) or between treatment groups (AMR versus AMR/Paced, AMR versus MIL, AMR/ Paced versus MIL/Paced, or MIL versus MIL/Paced). There were also no significant differences in the proportion of patients paced in each treatment group at any time during the study.
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at baseline, 819 + 62 vs 802 + 68 dynes * s * cmP5 at 5 min, and 702 & 56 vs 712 + 70 dynes * s * at 10 min). Likewise, there were no significant differences in pulmonary vascular resistance in patients receiving phenylephrine compared with those not receiving phenylephrine (amrinone versus amrinone/phenylephrine 161 + 121 vs 150 + 26 dynes * s * cme5 at baseline, 121 + 19 vs 119 + 10 dynes * s * cme5 at 5 min, and 95 2 10 vs 95 + 10 dynes * s * crne5 at 10 min; milrinone versus milrinone/phenylephrine 170 + 26 vs 230 2 33 dynes * s * cme5 cmm5 at baseline, 141 2 34 vs 180 + 34 dynes * s * cme5 at 5 min, and 116 t 21 vs 163 t 33 dynes * s * at 10 min). There was no difference in the number of patients receiving an intraaortic transfusion of blood from the CPB apparatus or the total volume transfused after either drug (Table 3) . Approximately half of the patients in each treatment group required volume infusion during the lo-min study interval (15 of 22 vs 17 of 22, P = NS in the amrinone and milrinone treatment groups, respectively). Patients requiring phenylephrine during the study interval were no more likely to receive volume transfusion than those who did not require phenylephrine (amrinone group 7 of 11 patients who did not require phenylephrine received an average of 368 + 65 mL, whereas 8 of 11 patients who required phenylephrine received an average of 394 +-69 mL [I' = NS]; milrinone group 8 of 11 patients who did not require phenylephrine received an average of 329 ? 63 mL, whereas 9 of 11 patients who required phenylephrine received an average of 395 + 65 mL [I' = NS]).
Discussion
Earlier studies have examined the hemodynamic effects of either amrinone or milrinone alone; this is the first blind, prospective, randomized, multicenter comparison of the two drugs. Our study identified minimal hemodynamic differences between amrinone 1.5 mg/kg and milrinone 50 pg/kg when administered immediately after separation from CPB. Both the initial and the second dose of each drug increased the CI compared with baseline. Central venous pressure was statistically significantly higher in the amrinone group at baseline and five minutes; however, we do not believe that these small differences were of clinical importance.
The hemodynamic effects of amrinone have been previously examined in patients undergoing elective cardiac surgery. In a study of 10 cardiac surgical patients receiving a bolus of 1.5 mg/kg of amrinone immediately after CPB, the CI increased from 3.0 -t 0.2 L * mm-i * rn-' to 4.0 + 0.2 L * mini * m-' 10 minutes after drug administration (4). The magnitude of the increase in CI (i.e., 1.0 L * mini * mb2) was identical to that found in our current study. Although the total dose of amrinone given was the same in both studies, we chose to give two separate boluses separated by a 5-minute interval in the present study. This two-dose regimen was designed to derive doseresponse information in addition to the overall effect of the loading dose. There were no significant differences in CI after milrinone versus amrinone administration at the 5-minute time point (after the first halfloading dose bolus). However, the initial dose of amrinone seemed to provide a higher fraction of the total drug effect than the initial dose of milrinone. Based on pharmacokinetic analysis, Bailey et al. (8) concluded that 0.75 mg/kg is an inadequate loading dose after CPB and that additional increases in CI could occur with doses up to 1.5 mg/kg. In contrast, Lathi (10) reported a 65% increase in CI after 0.75 mg/kg amrinone with no further increase in CI after the administration of an additional 0.75 mg/kg bolus 30 minutes later. Our data support the earlier hypotheses of Bailey et al. (8)-a further increase in CI occurs with a second 0.75 -mg/kg bolus of amrinone administered within approximately 5 minutes of the initial dose.
The hemodynamic effects of milrinone have also been previously reported in patients undergoing elective cardiac surgery. Butterworth et al. (6) administered milrinone to 29 patients undergoing cardiac surgery in doses ranging from 25 to 75 pg/kg immediately after CPB. In the group receiving a single bolus of 50 pg/kg, the CI increased from 2.3 + 0.1 to 3.4 ? 0.2 L e mine1 . m-' (68% increase) by five minutes after administration.
Kikura et al. (7) administered n-&none to 37 patients undergoing cardiac surgery in doses of 50 pg/kg and 75 pg/kg alone or followed by continuous infusions. Ten minutes after administration, the CI had risen from 2.2 + 0.5 to 3.5 t 0.5 L * mini * me2 after the administration of 50 pg/kg milrinone. Similar effects on CI were evident as early as five minutes after the administration of either dose. Thus, the magnitude and time course of inotropic effects after the administration of milrinone reported in our study were similar to those reported earlier (6,7).
Our original hypothesis was that amrinone and milrinone would produce similar hemodynamic changes. However, no statistical method can demonstrate complete equivalence. The approach to testing for equivalency has been described in detail by Freidman, et al. (11) . Using this approach, we were able to construct a 95% confidence interval for the difference in CI after either amrinone or milrinone administration (from -0.1 to 0.3 L * mm-i . m-'). Thus, with 95% confidence, our data demonstrate that the true difference in CI 10 minutes after the administration of either 1.5 mg/kg amrinone or 50 pg/kg milrinone lies between -0.1 and 0.3 L * mm-' * m-, a clinically inconsequential amount. This supports our original hypothesis that the two drugs can produce similar increases in CI.
We observed a small, statistically significant increase in MAP after the administration of amrinone ( Figure 2 ). No change in MAP was seen after milrinone administration.
Our study design called for the administration of phenylephrine if MAP decreased below 65 mm Hg despite maintainence of pulmonary artery pressures above 10 mm Hg. Because only half of the patients in each treatment group required phenylephrine during the study interval, we were able to examine its effect on MAP (Figure 2) . The changes in MAP were similar regardless of whether patients required phenylephrine, which suggests that the observed changes in MAP were independent of phenylephrine use.
PDE inhibitors (both amrinone and milrinone) result in decreases in systemic vascular resistance (4,6); volume administration and/or phenylephrine use may be required to counteract this decrease. Our goal was to maintain similar conditions of both preload and afterload while comparing the effect of each drug on CI. We found that both amrinone and milrinone led to a significant decrease in systemic and pulmonary vascular resistances, which were similar in magnitude 1998;86:683-90 CARDIOVASCULAR ANESTHESIA
to those reported previously (4,6). There were no significant differences in either systemic or pulmonary vascular resistances between those patients who received phenylephrine and those who did not. The average fluid volume infusion required, as well as the frequency of phenylephrine use, was similar after the administration of either amrinone or milrinone and agrees with that reported earlier (4,6). Although we attempted to maintain steady-state loading conditions throughout the study (transfusion of pump blood to maintain pulmonary artery diastolic pressure above 10 mm Hg and phenylephrine administration as needed to maintain MAP above 65 mm Hg), some variation in loading conditions undoubtedly occurred. These modest changes in MAP reflect only small changes in systemic vascular resistance and would not have significantly altered the observed changes in CI in these patients, who are not particularly afterloadsensitive (12).
Most patients in this study were paced via epicardial pacemaker leads. However, there was a small subset of patients whose pulse generators were nonoperative during hemodynamic measurements (Figure 3 ). All patients who were not paced had sinus rhythm at a rate X0 bpm; pacing was initiated during the study interval in only one patient (in the amrinone group) whose heart rate at baseline was 100 bpm, at five minutes was 102 bpm and decreased to a rate of <SO bpm, after which pacing was initiated (Figure 3) . Four patients in the milrinone group developed heart rates faster than 90 bpm, and the pulse generator was turned off after baseline measurements.
This group of patients who were not paced demonstrated an increase in heart rate of approximately lo-15 bpm after either amrinone or milrinone administration; however, none of these changes reached statistical significance. The findings are consistent with our previous reports of similar modest increases in heart rate after the administration of both milrinone (13) and amrinone (14). The mechanism of this increase in heart rate is unclear, but perhaps represents reflex tachycardia in response to peripheral vasodilation that occurs after the administration of either amrinone or milrinone. We did not observe arrhythmias in any patient during the study period, consonant with earlier findings in 29 cardiac surgical patients, in which only one episode of ventricular tachycardia was observed after the administration of 75 p/kg milrinone after CPB (6).
The present study was conducted at four different centers (three academic centers and one nonteaching center). Despite differing surgical practices, including different types and methods of delivering cardioplegia solutions, the results were similar at all four institutions. High Point had markedly shorter CPB and aortic cross-clamp times, yet the hemodynamic effects of the two drugs were similar at this and the other institutions, which suggests that similar hemodynamic effects could be expected in a variety of practice settings.
Certain limitations are evident in the experimental design of the present study. Because most patients were paced during the study interval, little information can be derived about the effect of either amrinone or milrinone on intrinsic heart rate in this setting. Half of the patients in each treatment group received phenylephrine, but no attempt was made to quantify phenylephrine use. Thus, the effects of amrinone and milrinone on systemic vascular resistance are obscured by the concurrent effects of variable doses of phenylephrine. Phenylephrine doses were typical of those used as a part of the standard practices of all participating institutions (lo-100 pg/min). Although the systemic vascular resistance observed in subgroups who received phenylephrine and those who did not were similar, it is possible that larger phenylehrine doses were required in one or the other of the inotrope treatment groups. We chose to study patients with mild to moderate cardiac dysfunction so that they could be safely separated from CPB before the start of the study. Patients with a CI ~2.7 L * mini * mP2 after separation from CPB were enrolled. We chose this end point, close to a normal value, to exclude patients who clearly did not need inotropic support under the usual practice guidelines of the participating institutions. We realize that the choice of a threshold enrollment CI value is arbitrary and that some of the patients enrolled in this study would not, under some other circumstances, have received inotropic drugs. Moreover, in typical clinical practice, phosphodiesteraseinhibitor inotropes may be administered before separation from CPB. Our study design allowed us to establish the hemodynamic effects of each inotrope relative to true baseline measurements.
Although dosing of inotropic agents seems to be similar in those with moderate cardiac dysfunction and those with severe cardiac dysfunction (4,5), it is possible that the magnitude of the hemodynamic effects of these two drugs in patients with severe cardiac dysfunction might differ from our present findings. Finally, both amrinone and milrinone are typically administered by continuous infusion after a loading dose is administered. We did not examine the hemodynamic effects of the two drugs well after the administration of the loading dose. However, the hemodynamic effects of both amrinone (5) and milrinone (6) seen after a loading dose are maintained over time when the drugs are given by continuous infusion.
Because the hemodynamic effects of amrinone and milrinone are similar, decisions regarding the use of these drugs should include other considerations. Thrombocytopenia was noted in 2.4% of 462 patients severely ill with congestive heart failure who received short-term amrinone infusions (15). The manufacturer RATHMELL ET AL. AMRINONE VS 1998;86:683-90 reports a 0.4% incidence of thrombocytopenia among 480 patients who received IV milrinone (9) but does not specify the patient population or dosage regimen for these patients. We did not evaluate thrombocytopenia in this study, and we studied an insufficient number of patients to compare the incidence of thrombocytopenia after amrinone or milrinone administration. Based on current acquisition costs in the United States (provided by the manufacturer), an equipotent adult loading dose (for a 70-kg patient) followed by a 24-hour infusion of amrinone costs approximately twice as much as an equipotent dose of milrinone ($518.00 vs $286.39). Given the similar hemodynamic effects of amrinone 1.5 mg/kg and milrinone 50 pg/kg, as demonstrated in our study, the lower reported incidence of thrombocytopenia and the lower cost of milrinone both argue in favor of using it, rather than amrinone, in adults requiring inotropic support after cardiac surgery.
